192 Shares in Eli Lilly and Company (NYSE:LLY) Acquired by Strid Group LLC

Strid Group LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 192 shares of the company’s stock, valued at approximately $148,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Serenus Wealth Advisors LLC acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $331,000. Arlington Financial Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 17.3% in the 4th quarter. Arlington Financial Advisors LLC now owns 508 shares of the company’s stock valued at $392,000 after buying an additional 75 shares in the last quarter. Kingsview Wealth Management LLC grew its position in shares of Eli Lilly and Company by 16.8% in the 4th quarter. Kingsview Wealth Management LLC now owns 63,845 shares of the company’s stock valued at $49,288,000 after buying an additional 9,166 shares during the last quarter. Apollon Wealth Management LLC raised its stake in Eli Lilly and Company by 38.1% during the 4th quarter. Apollon Wealth Management LLC now owns 19,651 shares of the company’s stock worth $15,171,000 after acquiring an additional 5,421 shares in the last quarter. Finally, Apollon Financial LLC boosted its stake in Eli Lilly and Company by 4.9% in the fourth quarter. Apollon Financial LLC now owns 1,577 shares of the company’s stock valued at $1,218,000 after acquiring an additional 74 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LLY. Deutsche Bank Aktiengesellschaft cut their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Wolfe Research started coverage on Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective for the company. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday. Wells Fargo & Company cut their target price on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Finally, Truist Financial increased their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $997.50.

Eli Lilly and Company Stock Up 0.9 %

Eli Lilly and Company stock opened at $878.09 on Monday. The stock’s 50 day moving average price is $789.87 and its 200 day moving average price is $843.31. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53. The company has a market cap of $833.58 billion, a PE ratio of 74.99, a price-to-earnings-growth ratio of 1.87 and a beta of 0.42. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. On average, sell-side analysts predict that Eli Lilly and Company will post 23.33 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a yield of 0.68%. Eli Lilly and Company’s dividend payout ratio (DPR) is 51.24%.

Eli Lilly and Company announced that its Board of Directors has approved a stock buyback program on Monday, December 9th that permits the company to buyback $15.00 billion in outstanding shares. This buyback authorization permits the company to buy up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.